2002
Noven’s Media Center gives you immediate access to current and archived press releases.
Please note that news releases appearing on this website are presented for historical reference, have not been updated for current events, and are current only as of their respective dates of issuance.
- Noven Presents Pre-clinical Study Data At AAPS Annual Meeting - (11/19/02)
- Noven Reports Third Quarter Earnings Per Share of $0.12 - (10/31/02)
- Noven Announces Positive Phase III Study Results For Once-daily ADHD Transdermal Patch - (10/24/02)
- FDA Accepts New Drug Application For Noven's Once-daily MethyPatch - (08/27/02)
- Noven Announces U.S. Launch of New Low Dose Vivelle-Dot Patch - (08/19/02)
- Noven Achieves Record Results For Second Quarter - (08/01/02)
- Noven Comments On National Cancer Institute HRT Study - (07/17/02)
- Noven Comments On Women's Health Initiative HRT Study - (07/10/02)
- Noven Expects Second Quarter Earnings To Exceed Prior Public Guidance - (07/02/02)
- Noven Submits New Drug Application For Once-daily MethyPatch - (06/27/02)
- Noven Appoints Karen Frank, MD As Vice President of Clinical Research & Regulatory Affairs - (06/24/02)
- Noven Announces Presentation of Data On Effect of Transdermal Combination HRT On Mood And Libido of Postmenopausal Women - (06/11/02)
- Noven Announces FDA Approval of Vivelle-Dot Additional Indication And New Low Dose Strength - (05/20/02)
- Noven Announces Results of 2002 Annual Shareholders' Meeting - (05/16/02)
- Noven Reports First Quarter Earnings Per Share of $0.06 - (04/30/02)
- Noven Announces Estradot Launched In Germany - (04/09/02)
- Noven Announces Success Of Phase III Study For Once-daily MethyPatch - (04/01/02)
- Noven Reports 2001 Earnings Per Share of $0.51 - (02/26/02)
- Noven Completes Patient Enrollment For MethyPatch Phase III Clinical Trial - (02/07/02)
